J Passweg
Passweg, Jakob R. 1959-
Passweg, J. R.
Passweg, Jacob
VIAF ID: 101144782698093863799 (Personal)
Permalink: http://viaf.org/viaf/101144782698093863799
Preferred Forms
- 100 0 _ ‡a J Passweg
- 100 1 _ ‡a Passweg, J. R.
-
- 100 1 _ ‡a Passweg, Jakob R. ‡d 1959-
4xx's: Alternate Name Forms (5)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion | |
Cytopenia and hematopoietic recovery after low intensity conditioning transplants | |
Hematopoietic SCT in Europe 2013 recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants | |
Hematopoietic stem cell transplantation activity in Europe. | |
Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party | |
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. | |
Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections | |
Myeloid leukemia and myelodysplastic syndrome relapsing as granulocytic sarcoma | |
Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow. | |
Myeloproliferative disorders: complications, survival and causes of death | |
[Neuropathy associated with monoclonal gammopathy (dysglobulinemia)] | |
Novel therapeutic options in Acute Myeloid Leukemia | |
Numerical impairment of nestin | |
Obstacles to Widening Biosample Research. | |
Octenidine hydrochloride for the care of central venous catheter insertion sites in severely immunocompromised patients | |
[Optimizing plasma cell content in bone marrow aspirates] | |
Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression | |
Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia | |
Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. | |
Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT | |
Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment | |
Patient and product factors affecting platelet transfusion results | |
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease | |
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation | |
Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy. | |
Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. | |
Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation | |
Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. | |
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation | |
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. | |
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party | |
Protective antibody responses to influenza A/H1N1/09 vaccination in children with celiac disease | |
Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation | |
Pustular eruption at the site of subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor | |
Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia | |
Quality of life and social integration after allogeneic hematopoietic SCT | |
Recent improvement in outcome of unrelated donor transplantation for aplastic anemia | |
Related donor bone marrow transplantation for chronic myelogenous leukemia. | |
Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency | |
Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia | |
Reply to: Towards a rational graft-versus-host disease prophylaxis: rituximab should not be forgotten. | |
Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. | |
Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine | |
Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. | |
Role of primacy of birth in HLA-identical sibling transplantation | |
Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases | |
Role of tumour angiogenesis in haematological malignancies | |
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | |
S235: A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of the S1P receptor modulator KRP203 in subjects with hematological malignancies | |
Severe anemia after trans-catheter arterial chemoembolization-an unusual presentation of hemoglobin Zurich | |
Short- and long-term outcome after lung resection for invasive pulmonary aspergillosis | |
Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood | |
The Survey on Cellular and Engineered Tissue Therapies in Europe in 2013. |